Horse tranquiliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


Parkinson Italia White paper event lead

Europe

Parkinson Italia launches multi-stakeholder White Book research project

Major new study will help create ‘patient wellbeing scale’

READ MORE
dystonia

Resources & Tools

Cramping more than your style

Register for this free hour-long webinar

READ MORE
September

Agenda

September 2018

Highlights: Cycle Venice to Rome, Italy

READ MORE